Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients
1 other identifier
observational
100
0 countries
N/A
Brief Summary
- 1.Evaluate the diagnostic value of long noncoding RNA (CCAT1) expression by RT-PCR in peripheral blood in colorectal cancer patients versus normal healthy control personal.
- 2.Evaluate the clinical utility of detecting long noncoding RNA (CCAT1) expression in diagnosis of colorectal cancer patients \& its relation to tumor staging.
- 3.Evaluate the clinical utility of detecting long noncoding RNA (CCAT1) expression in precancerous colorectal diseases.
- 4.Compare long noncoding RNA (CCAT1) expression with traditional marker; carcinoembryonic antigen (CEA) and Carbohydrate antigen 19-9 (CA19-9) in diagnosis of colorectal cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2020
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 12, 2020
CompletedFirst Posted
Study publicly available on registry
February 17, 2020
CompletedStudy Start
First participant enrolled
December 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2021
CompletedJuly 8, 2020
February 1, 2020
3 months
February 12, 2020
July 7, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Evaluate the diagnostic value of long noncoding RNA (CCAT1) expression
Evaluate the clinical utility of detecting long noncoding RNA (CCAT1) expression in diagnosis of colorectal cancer patients \& its relation to tumor staging.
baseline
Study Arms (3)
Control group
The control population comprised normal healthy individuals.
Precancerous group
patients with precancerous colorectal diseases
CRC group
patients with colorectal cancer
Interventions
Eligibility Criteria
normal healthy individuals. precancerous colorectal diseases colorectal cancer
You may qualify if:
- Patients newly diagnosed with colorectal cancer
You may not qualify if:
- \. Patients with colorectal cancer that had been received chemotherapy, radiotherapy or surgical treatment.
- \. History of non-precancerous benign colorectal diseases (Irritable bowel syndrome, colitis, appendicitis, diverticulitis, paralytic ileus \& intussusception).
- \. History of benign or malignant tumors in other organs.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Zhao B, Lu M, Wang D, Li H, He X. Genome-Wide Identification of Long Noncoding RNAs in Human Intervertebral Disc Degeneration by RNA Sequencing. Biomed Res Int. 2016;2016:3684875. doi: 10.1155/2016/3684875. Epub 2016 Dec 20.
PMID: 28097131BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CROSSOVER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant lecturer
Study Record Dates
First Submitted
February 12, 2020
First Posted
February 17, 2020
Study Start
December 1, 2020
Primary Completion
March 1, 2021
Study Completion
September 1, 2021
Last Updated
July 8, 2020
Record last verified: 2020-02